Diagnosis of Congenital Hypogonadotropic Hypogonadism
Congenital hypogonadotropic hypogonadism (CHH) is diagnosed through a combination of clinical evaluation, hormonal assessment, brain MRI, and genetic testing—the GnRH stimulation test is NOT routinely used or recommended for diagnosis. 1
Clinical Evaluation
The diagnosis begins with identifying specific clinical features:
In males:
- Absent or incomplete puberty after age 14
- Micropenis and small testicular volume (<4 mL in severe cases, <10 mL in partial forms)
- Lack of virilization (unmuted voice, beardlessness, absent muscle development)
- Tall stature with gynoid obesity
- Decreased libido, erectile dysfunction, or infertility in adults 1
In females:
- Primary amenorrhea (90% of cases)
- Absent or minimal breast development
- Oligomenorrhea or infertility in milder forms 1
Associated features suggesting Kallmann syndrome:
- Anosmia or hyposmia (must be formally assessed—questioning alone is insufficient; olfactometry is necessary for reliable diagnosis)
- Unilateral renal agenesis
- Cleft lip/palate
- Dental agenesis
- Mirror movements (synkinesis) in 5-15% of cases
- Central deafness 1, 2
Hormonal Assessment
The diagnostic hormonal profile consists of:
- Low serum testosterone in males (measured before 10 AM after overnight fast, away from acute illness)
- Low or inappropriately normal LH and FSH levels (not elevated as would occur in primary gonadal failure)
- Low inhibin B levels
- Measure serum prolactin to exclude prolactinoma 3, 2, 4
Critical point: Two measurements with the same assay are preferred for borderline values. The combination of low sex steroids with low-to-normal (not elevated) gonadotropins distinguishes central from primary hypogonadal disorders 3, 2.
Why GnRH Stimulation Testing Is NOT Used
Unlike growth hormone deficiency where stimulation testing is standard 3, GnRH stimulation tests are not recommended for diagnosing CHH. The diagnosis relies on basal hormone measurements showing the characteristic pattern of low sex steroids with inappropriately low/normal gonadotropins 2, 4. Single GH measurements are unhelpful for GH deficiency 3, but for CHH, the basal gonadotropin pattern itself is diagnostic when combined with clinical features.
Imaging Studies
Brain and hypothalamic-pituitary MRI is mandatory to:
- Rule out pituitary tumors or infiltrative lesions
- Identify structural abnormalities (pituitary hypoplasia, ectopic posterior pituitary)
- Detect olfactory bulb abnormalities in Kallmann syndrome
Important caveat: Normal MRI does not exclude CHH diagnosis 1.
Genetic Testing
Genetic analysis should be performed using next-generation sequencing (NGS) panels covering the most prevalent CHH genes 1:
For Kallmann syndrome (with anosmia):
- KAL1/ANOS1 (X-linked)
- FGFR1, PROKR2, PROK2
For normosmic CHH:
- GNRHR, GNRH1
- KISS1R, KISS1
- TAC3, TACR3
Genetic diagnosis is identified in 7-10% of cases overall, with higher yield in familial cases (29.5%) versus sporadic cases (2.6%) 1.
Differential Diagnosis to Exclude
Before confirming CHH, rule out:
- Constitutional delay of puberty (the main differential in adolescents)
- Pituitary tumors or infiltration (via MRI)
- Juvenile hemochromatosis
- Systemic illness affecting nutritional status
- Functional hypothalamic amenorrhea (acquired, not congenital)
- Multiple pituitary hormone deficiencies (assess all anterior pituitary axes) 2, 5
Diagnostic Algorithm
- Clinical assessment: Identify pubertal delay/absence, measure testicular volume, assess olfaction formally
- Hormonal testing: Morning testosterone, LH, FSH, prolactin (away from acute illness)
- MRI brain/pituitary: Rule out structural lesions
- Assess other pituitary axes: Exclude multiple pituitary hormone deficiencies
- Genetic testing: NGS panel of CHH genes, especially if familial or syndromic features present
The diagnosis is clinical and biochemical—stimulation testing with GnRH plays no role in establishing the diagnosis of CHH.